Since its pioneer days, liver transplantation for malignant liver tumors has decreased worldwide, the present percentage within Europe being roughly 15%. There are mainly two reasons for this decrease: First, liver transplantation has matured to an officially recognized therapy for a wide variety of benign endstage liver diseases, favoring patients with these indications in the competition for the sparse donor organs. Secondly, the overall results in tumor patients remained discouraging with unacceptably high, inevitably lethal tumor recurrence rates. In this article, a review of the literature is presented along with our own restrictive concept based mainly on the encouraging Pittsburgh experience with small ( < 5cm largest diameter), solitary hepatocellular carcinomas (HCC). Eight (=7%) of our first 114 patients were transplanted for unresectable liver cancers, six of them are presently without tumor recurrence (three to 23 months observation time). One patient died from tumor recurrence and one from tumor unrelated complications. In addition, four patients were found to have incidental carcinomas: Three HCC, all alive and without tumor and one cholangiocarcinoma presenting with peritoneal carcinomatosis five months postoperatively. Cholangiocarcinomas, metastatic liver disease (except neuroendocrine tumors), and sarcomas as well as extrahepatic tumor spread are excluded from transplantation at our institution. The importance, technique and timing of staging laparotomy is emphasized.

Keywords:
Malignant liver tumors, Orthotopic liver transplantation, Hepatocellular carcinoma
This content is only available via PDF.
© 1991 S. Karger AG, Basel
1991
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.